Intensive Initial Oral Anticoagulation and Shorter Heparin Treatment in Deep Vein Thrombosis

Summary

In order to investigate whether a more intensive initial oral anticoagulation still would be safe and effective, we performed a prospective randomized study in patients with deep vein thrombosis. They received either the conventional regimen of oral anticoagulation (“low-dose”) and heparin or a more intense oral anticoagulation (“high-dose”) with a shorter period of heparin treatment.

In the first part of the study 129 patients were randomized. The “low-dose” group reached a stable therapeutic prothrombin complex (PT)-level after 4.3 and the “high-dose” group after 3.3 days. Heparin was discontinued after 6.0 and 5.0 days respectively. There was no difference in significant hemorrhage between the groups, and no clinical signs of progression of the thrombosis.

In the second part of the study another 40 patients were randomized, followed with coagulation factor II, VII, IX and X and with repeated venograms. A stable therapeutic PT-level was achieved after 4.4 (“low-dose”) and 3.7 (“high-dose”) days, and heparin was discontinued after 5.4 and 4.4 days respectively. There were no clinical hemorrhages, the activity of the coagulation factors had dropped to the same level in both groups at the time when heparin was discontinued and no thromboembolic complications occurred.

Our oral anticoagulation regimen with heparin treatment for an average of 4.4-5 days seems safe and reduces in-patient costs.

Key words

Deep-vein thrombosis - Oral anticoagulation - Warfarin - Initial therapy - Coagulation factors

• References

• 1 Allen EV, Barker NW, Wangh JM. A preparation from spoiled sweet clover. J Am Med Ass 1942; 120: 1009-1015
• 2 Coon WW, Willis III PW, Symons MJ. Assessment of anticoagulant treatment of venous thromboembolism. Ann Surg 1969; 170: 559-568
• 3 Deykin D, Wessler S, Reimer SM. Evidence for an antithrombotic effect of Dicumarol. Am J Physiol 1960; 199: 1161-1164
• 4 Hoak JC, Connor WE, Warner ED, Carter JR. The antithrombotic properties of coumarin drugs. Ann Intern Med 1961; 54: 73-81
• 5 Coon WW, Willis III PW. Thromboembolic complications during anticoagulant therapy. Arch Surg 1972; 105: 209-212
• 6 O’Reilly RA, Aggeler PM. Studies on coumarin anticoagulant drugs. Initiation of Warfarin therapy without a loading dose Circulation 1968; 38: 169-177
• 7 Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972; 104: 134-144
• 8 Bygdeman S, Aschberg S, Hindmarsh T. Venous plethysmography in the diagnosis of chronic venous insufficiency. Acta Chir Scand 1971; 137: 423-428
• 9 Schulman S. Influence of heparin on different analyses of the prothrombin complex. OPMEAR 1982; 27: 61-62
• 10 Koller F, Loeliger A, Duckert F. Experiments on a new clotting factor, Factor VII. Acta Haematol 1951; 6: 1-16
• 11 Hardistry RM, MacPherson JC. An one stage Factor VIII (antihemophilic globulin) assay and its use on venous and capillary plasma. Thrombos Diathes Haemorrh 1962; 7: 215-229
• 12 Marder VJ, Shulman NR. Clinical aspects of congenital factor VII deficiency. Am J Med 1964; 37: 182-194
• 13 Godal HC, Madsen K, Nissen-Meyer R. Thrombo-embolism in patients with total proconvertin (factor VII) deficiency: a report on two cases. Acta Med Scand 1962; 171: 325-327
• 14 Hall CA, Rapaport S. et al. A clinical and family study of hereditary proconvertin (factor VII) deficiency. Am J Med 1964; 37: 172-181
• 15 Gershwin ME, Gude JK. Deep vein thrombosis and pulmonary embolism in congenital factor VII deficiency. N Engl J Med 1973; 288: 141-142
• 16 Kisiel W. Human plasma protein C: isolation, characterization and mechanism of activation by alpha thrombin. J Clin Invest 1979; 64: 761-769
• 17 Epstein DJ, Bergum PW, Rapaport SI. Kinetics of protein C-depression after coumarin administration. (Abstract.) Circulation 1983; 68 suppl (Suppl. 03) 1264
• 18 Viets CH, Gebauer D. Coumarin necrosis. Ger Med Mth 1968; 13: 23-26
• 19 Howitt AJ, Skinner C, Williams AJ. Warfarin-induced vasculitis: A dose-related phenomenon in susceptible individuals. Postgrad J 1982; 58: 233-234
• 20 Koch-Weser J. Coumarin necrosis. Ann Intern Med 1968; 68: 1365-1367
• 21 Horn JR, Danziger LH, David RJ. Warfarin-induced skin necrosis: Report of four cases. Am J Hosp Pharm 1981; 38: 1763-1768
• 22 Faraci PA. Warfarin-induced skin necrosis, an obscure complication of anticoagulant therapy. Int J Dermatol 1982; 21: 329-330
• 23 Hofmann V, Frick PG. Repeated occurrence of skin necrosis twice following coumarin intake and subsequently during decrease of vitamin K dependent coagulation factors associated with cholestasis. Thromb Haemostas 1982; 48: 245-246
• 24 Broekmans AW, Bertina RM, Loeliger EA, Hofmann V, Klingemann H-G. Protein C and the development of skin necrosis during anticoagulation therapy. Thromb Haemostas 1983; 49: 251
• 25 Hull R, Delmore T, Genton E, Hirsh J, Gent M, Sackett D, McLoughlin D, Armstrong P. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301: 855-858
• 26 Nylander G, Olivecrona H. The phlebographic pattern of acute leg thrombosis within a defined urban population. Acta Chir Scand 1976; 142: 505-511